Annual Meeting of the American Society of Clinical Oncology (ASCO) 2019. - In children with TRK fusion cancer, the overall response rate.
Background: A broad range of pediatric and adult malignancies harbor TRK fusions involving the NTRK1, NTRK2, and NTRK3 genes. The highly-selective TRK inhibitor, larotrectinib, has previously shown a high overall response rate (ORR) and a favorable safety profile in patients (pts.
N Engl J Med. 2018 Feb 22;378(8):731-739. doi: 10.1056/NEJMoa1714448. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.